Coronary Artery Disease Got You Down? Hang in there. Help is on the way!

By HeartHawk Latest Reply 2012-04-15 23:00:28 -0500
Started 2011-01-08 20:32:23 -0600

I just came across an article written by Dr. Melissa Walton-Shirley on the new experimental drug anaceptrapib and it was glowing. Much has been written about this drug and it promise for the future. But, hearing this from the mouth of Dr. Walton-Shirley is something special.

In the past Dr. Walton-Shirley and I have had some pointed disagreements as I found her perspective on heart disease prevention to be a little too "traditional" for my tastes. Dr. Walton-Shirley is not easily impressed. If she thinks this is something special then we should all keep our fingers crossed and fight on - perhaps the "cavalry" is on the way for many of us!

The next series of test may determine if anacetrapib not only dramatically raises HDL (it does) but also dramtically boosts REMOVAL of plaque from arteries making it the first practical drug to do so (ETC-216, also known as Apo-A1 Millano, already does it but requires injections and is VERY expensive and not yet FDA approved).

Anyone here enrolled in an anacetrapib trial?

Here is another link to the article

5 replies

CRASH1219 2011-07-09 14:19:19 -0500 Report

This sounds good.I have low HDL.Do you think this will be available soon?

HeartHawk 2011-07-10 06:56:57 -0500 Report

There is a 30,000 patient trial going on (the REVEAL trial)

but Merck says it won't file for FDA approval until 2015. Other medical commentators are more optimistic believing the trial results will be so ovewhelmingly positive they will end the trial early. If this occurs look for Merck to push for fast-track FDA approval for "humanitarian" purposes (as well as profit purposes)!


DTJ1 2011-08-01 22:29:20 -0500 Report

HH - has anyone seen any updates on this recently - I looked back through all the media and have not seen anything. Too soon I suppose?

HeartHawk 2012-04-15 23:00:28 -0500 Report


Phase 3 results just in.

The study showed that patients receiving anacetrapib had their LDL levels fall by 38% compared to those in the placebo group and had a 138% gain in HDL levels. Patients in both groups had average LDL levels of about 80 upon study entry, which is considered in the healthy range, and had HDL levels of about 40. Patients taking anacetrapib had their LDL levels fall to about 45, on average, and their HDL levels rise to 101, while those in the placebo group had an average LDL of 77 and an HDL of 46

Moving to final large scale study before FDA approval

Here's an article.